Trevi Therapeutics is a clinical-stage biopharmaceutical company developing therapies for chronic cough in serious lung disease. Its lead candidate is an oral extended-release form of nalbuphine (Haduvio) aimed at conditions such as idiopathic pulmonary fibrosis–related cough and refractory chronic cough. The company focuses on advancing late-stage clinical programs rather than marketed products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -12.3 | — |
| Q3 2025 | 0 | — | -11.8 | — |
| Q4 2025 | 0 | — | -8.3 | — |
| Q1 2026 | 0 | — | -13.2 | — |
| Q2 2026 | 0 | — | -17.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Schrödinger, Inc. (SDGR), UroGen Pharma Ltd. (URGN), Vir Biotechnology, Inc. (VIR), Braveheart Bio, Inc. (BRVE), Happen, Inc. (HAPN), Personalis, Inc. (PSNL)